Newsfeeds Archive - Spark Newswire

3 minute read

enVVeno Medical Reports Q3 2023 Financial Results And Provides Corporate Update; The Company Ended The Quarter With $25.7M In Cash And Investments

October 26, 8:24 AM

- $51.4 million cash on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025- Achieved full enrollment for VenoValve® U.S. pivotal trial- Expedited

NVNO

2 minute read

enVVeno Medical Announces Private Placement Of $28M Conducted As An At-The-Market Offering Under Nasdaq Rules At A Purchase Price Per Share Of Common Stock And Warrants Of $5.806

By Benzinga Newsdesk

October 6, 8:58 AM

Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data from the VenoValve pivotal trialUp to an additional $41 million

NVNO

3 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

July 19, 1:31 PM

Gainers enVVeno Medical (NASDAQ:NVNO) shares moved upwards by 29.4% to $4.71 during Wednesday’s regular session. Trading volume for…

AMRN

3 minute read

enVVeno Medical Provides Enrollment Update For Ongoing VenoValve U.S. Pivotal Study And Announces Upcoming Investor And KOL Events

By Happy Mohamed

July 5, 8:22 AM

57 patients enrolled to date in the SAVVE® study Full SAVVE enrollment expected by year-end July 13 - Company to participate in investor event to further discuss enrollment July 18 - KOL event with two SAVVE

NVNO

9 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

May 24, 12:49 PM

On Wednesday, 129 stocks made new 52-week lows.

ADMP

3 minute read

enVVeno Medical Successfully Passes Preliminary FDA Safety Review For The VenoValve U.S. Pivotal Study

By Benzinga Newsdesk

November 7, 9:46 AM

The Company submitted safety data for the first 20 patients enrolled in the ongoing SAVVE U.S. pivotal study for the VenoValve Following the initial safety data review by the FDA, the SAVVE study is cleared to continue

NVNO

Latest news

enVVeno Medical Reports Q3 2023 Financial Results And Provides Corporate Update; The Company Ended The Quarter With $25.7M In Cash And Investments

enVVeno Medical Announces Private Placement Of $28M Conducted As An At-The-Market Offering Under Nasdaq Rules At A Purchase Price Per Share Of Common Stock And Warrants Of $5.806

12 Health Care Stocks Moving In Wednesday’s Intraday Session

enVVeno Medical Provides Enrollment Update For Ongoing VenoValve U.S. Pivotal Study And Announces Upcoming Investor And KOL Events

Stocks That Hit 52-Week Lows On Wednesday

enVVeno Medical Successfully Passes Preliminary FDA Safety Review For The VenoValve U.S. Pivotal Study